Sol-Gel Technologies (SLGL) Share-based Compensation (2020 - 2025)
Sol-Gel Technologies (SLGL) reported Share-based Compensation of $100000.0 for Q2 2025, down 63.64% year-over-year from $275000.0 in Q2 2024, and down 63.64% quarter-over-quarter from $275000.0 in Q2 2024.
Sol-Gel Technologies (SLGL) Share-based Compensation (2020 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has 6 years of Share-based Compensation data on file, last reported at $100000.0 in Q2 2025.
- Share-based Compensation for Q2 2025 came in at $100000.0, down 63.64% year-over-year; the trailing twelve-month figure through Jun 2025 was $1.2 million (down 8.45% YoY), and the FY2025 annual result was $82000.0, down 89.57% from the prior year.
- Share-based Compensation declined to $100000.0 in Q2 2025 per SLGL's latest filing, from $275000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $498000.0 in Q2 2023 and troughed at $100000.0 in Q2 2025.
- A 5-year average of $287600.0 and a median of $275000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 65.26% in 2022, then slumped 63.64% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $213000.0 in 2021, then jumped by 65.26% to $352000.0 in 2022, then jumped by 41.48% to $498000.0 in 2023, then sank by 44.78% to $275000.0 in 2024, then tumbled by 63.64% to $100000.0 in 2025.
- Business Quant data shows SLGL's Share-based Compensation at $100000.0 in Q2 2025, $275000.0 in Q2 2024, and $498000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2023 | 498,000.00 |
| Jun 30, 2023 | 498,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Jun 30, 2021 | 213,000.00 |
| Jun 30, 2021 | 213,000.00 |
| Jun 30, 2020 | 315,000.00 |
| Jun 30, 2020 | 315,000.00 |